

Index

- A**
Abelcet[®], 187
Abou-Arab, T.W., 204
Abraxane[®], 187
Acrivis, A., 219
Adsorbed biomolecules, 99
Aerodynamic diameter, of inhaled particle, 192
Aerosols
 definition of, 206
 particle motion of, 213, 214
 as respiratory therapeutic agent, 191, 192
AFM examination
 basidiospores, 128
 bilayer, 153
 monolayers, 153, 154
 patterned collagen layers, 145–147
 PS surface, 99, 100
 surface coverage-thickness, adsorbed
 phases, 96, 97, 147
Agarwal, J.K., 202
Ahmadi, G., 201–204, 224, 239, 241, 243, 245,
 256–258, 263
Aidun, C.K., 269
Air-jet milling process, for pharmaceutical
 manufacturing, 176
Alberts, B., 258
Albumin adsorption, 147, 155
Alpha-lactalbumin, 131
Alveolar cavities, particle transport and
 deposition in, 256–258
Ambisome[®], 187
Amine functions, 142
Amorphous gate (bitmap), 2
Analyzer transmission function, 72, 73
Angle-resolved XPS
 sample charging
 and charge stabilization, 58–60
 flood gun energy, 59
 monochromatized X-ray beam, 58
 secondary electrons and photoelectrons,
 57–58
 semi-quantitative use of
 background shape, 89
 PP, 87
Angular asymmetry factor
 for photoelectron emission, 70
 for spectrometers, 71
Anjilvel, S., 239
Antara[™]. *See* Fenofibrate drug
Antibody-conjugated beads, and light scatter
 shifts of, 16
Arnason, G., 201, 202
Artefacts, 104, 105
Artoli, A.M., 263
ARXPS. *See* Angle-Resolved XPS
Asgharian, B., 204, 239
Asher, S.A., 289
Atherosclerosis, 264–267
AUC. *See* Extents of absorption
Auger electron kinetic energy, 64
Auger peaks
 and Auger parameter, 64, 65
 photoionization and, 63, 64
Azospirillum brasilense
 proteins, 112
 surface composition of, 122, 123
B
Bacillus subtilis
 C_{ox}/C for, 108
 N 1s peak of, 106, 107
 peak decomposition of, 110, 111
 wide scan XPS spectra of, 49
Background subtraction, 77, 78

- Bacterial adhesion, 131, 139
 Balashazy, I., 239
 Ball milling process, for pharmaceutical manufacturing, 176
 Baron, P.A., 206
 Basset-Boussinesq-Oseen equation, 201
 BBO. *See* Basset-Boussinesq-Oseen equation
 Bead–blood assays
 flow cytometry advantages in, 19
 using CD3 antibody–beads
 antibody lot dependence, 6, 7
 bead titer dependence, 7, 8
 factors affecting performance of, 4, 5
 Bead–blood mixing time, 5, 7
 Bead chemical sensors
 application for, 19
 Flow-Cal 575 fluorospheres, 18
 Bead probes
 biological cell assays, problems in, 16
 CD3 antibody–beads, 4–9
 for flow cytometric analysis, 1
 light scatter nanoparticle
 fluorescence emission, 17–27
 luminescence emission, 27–29
 Raman scattering, 32–37
 surface plasmon resonance, 15–17
 light scatter shifts, 16
 Bead suspension array technology, advantages of, 21
 BEM. *See* Boundary element method
 Berger, S.A., 258, 261, 262
 Binding energy, 46
 Biochemical compounds
 chemical functions of, 81–83
 peak components of, 80, 83
 Biocorrosion, thin copper films, 150
 Biodegradable polymers, 136
 Biofilms, material surface conditioning with, 129, 131
 Biomedical applications, 129
 materials, titanium implants, 135
 model systems, 153
 schematic representation of, 134
 Biomolecules, adsorption
 binary and ternary mixtures, 148
 from single protein solutions, 144
 Bio-PlexTM suspension array system, 21
 Biosorption process, 130
 Biosystems, 43
 Bisphosphonate ester, usage, 178
 Blood flow
 atherosclerosis, 264–267
 composition of, 259, 260
 DNS methods of, 267–270
 red cells flow behavior, 261–264
 rheology of, 260, 261
 Bogush, G. H., 284
 Bone formation, 135
 Boundary element method, 267
 Bradley (initial not found), 291
 Brady, J.F., 290
 Bremsstrahlung radiation, 53
 Brenner, H., 208, 261
 Brewing yeast. *See* *Saccharomyces cerevisiae*
 Britter, R.E., 202
 Brooke, J.W., 204
 Brownian motion process, 221–224
 Büchel, G., 294
 Budesonide particles, 177, 178, 191, 195
 Buerk, D.E., 258
 Buoyancy effect, of particle, 216, 217
 Burshteyn, A., 4, 25
- C**
 Cai, H., 265
 Calabrese, R.V., 201
 Cao, J., 204, 297
 Caro, C.G., 265
 Caruso, F., 297
 Caruso, R.A., 297
 CD3 antibody–beads
 bead–blood assays
 antibody lot dependence, 6, 7
 bead titer dependence, 7, 8
 factors affecting performance of, 4, 5
 bead-to-cell ratios for, 8, 9
 CD45 antibody–magnetic beads, 9
 CD3/CD3-PE competitive binding experiments, 7
 CD4+ lymphocytes
 antibody activation, and bead–blood mixing time, effects of, 5, 6
 micrographs of, 3, 4
 CD8+ lymphocytes, selective depletion of, 14
 CD38-PE biological assay, 19
 CdSe q-dotsTM, 29, 30
 CdS particles
 emission colors of, 28
 energy transfer, 30–32
 Cell assays
 needs for, 29, 30
 problems in, 16
 receptor sites and light scatter pattern, 16
 Cell membrane, 153
 Cells adhering, 131
 CFCs. *See* Chorofluorocarbons
 Chaffey, C., 261
 Chaffey, C.E., 261

- Chang, I-S., 256–258
 Channel plates, 56
 Channeltrons, 56
 Chan, T.L., 239
 Charge stabilization devices, 60
 Charnay, C., 297
 Chemical analysis, 43, 44
 Chemical functions
 of biochemical compounds, 83
 components of, 79, 80
 peak decomposition and assignment
 oxygen and nitrogen peak, 111
 of solids, 81, 82
 Chemical shifts, 135
 biochemical compounds, 80–87
 on oxygen and carbon, 80
 polymers, 79, 80
 Chen, B.T., 206
 Chen, C.P., 204
 Cheng, Y.S., 246, 253
 Chen (initial not found), 269
 Chen, J.F., 297
 Chen, Q., 204
 Cherukat, P., 218
 Chlorofluorocarbons, 191
 Ciftcioglu, M., 286
 Circulaire™ Aerosol Drug Delivery System
 jet nebulizer, 196
 Cleaver, J.W., 202
 Clickhaler®, 193
 Cohen, B.S., 239
 Cokelet, G.R., 262
 Collins, L.R., 205
 Colloidal crystals, 287
 Comer, J.K., 239
 Concentric hemispherical analyzer (CHA). *See*
 Electrostatic hemispherical analyzer
 Contact lenses, 158
 Continuous adlayer
 heterogeneity of zone, 91
 organic contamination influence on, 92, 93
 silicon wafers, 90
 Controlled precipitation, of pharmaceutical
 products, 177
 Corrsin, S., 201
Corynebacterium glutamicum, phosphate
 concentration of, 130
 Coulter cellular therapies, 14
 Coulter® EPICS™ Elite™ series flow
 cytometers, 1
 Coulter® STKS2B™ hematology analyzer
 assay
 for CD3+ lymphocytes
 antibody bead lots, 6, 7
 DF 8 (median angle light scatter) vs.
 Coulter volume, 5, 6
 vs. bead titers with whole blood, 7, 8
 Cremaphor® EL, 187
 Crowe, C.T., 204
 Cryofixation, 118
 Csanady, G.T., 201
 Cundy, K. C., 179
 Cunningham correction factor, 208, 209
 Cyclosporine, 177
- D**
 Danazol drug, 177, 179
 Dandy, D.S., 218
 Danocrine®. *See* Danazol
 ID3 antibody–ferrite bead titers
 effect on neutrophils, 12
 Darquenne (initial not found), 256
 Davies, C.N., 202
 Davies, P.F., 265
 De Kruif, C.G., 290
 Deleu, M., 153
 Dental implants, 135
 Derjaguin, B.V., 235
 Diatrizoic acid, usage, 189, 190
 Ding, E.-J., 269
 Direct numerical simulations, 204, 205
 for human blood flow, 267–270
 Discontinuous adlayer
 film organization, 96
 substratum
 peak intensity, 94
 plot of surface coverage, 95
 Diskhaler® inhalation device, 193
 Dispersed solids, 43, 44
 DMT model, for particle adhesion, 235, 237,
 238
 DNA synthesis, of hepatoma cells, 153
 DNS. *See* Direct numerical simulations
 Donnelly, J. P., 187, 188
 Doolen, G.D., 268
 Doxil®, 187
 DPI. *See* Dry powder inhaler device
 DPPC monolayers, 154
 Drag force and drag coefficient
 for liquid droplets, 209
 models for, 207
 wall effects on, 208
 Drolet, F., 205
 Drug dissolution time, 179
 Drug particles size, reduction of, 175, 176
 Drug residence time, 178, 179
 Drust, F., 204

- Druzhinin, O.A., 205
 Dry powder aerosols delivery, to lung, 192–194
 Dry powder inhaler device, 192
 Dulling, B.R., 266
 DuPin, M.M., 269
 Durst, F., 202
 Dwyer, H.A., 218
 Dye-embedded core-shell nanoparticles, 33
 Dynamic shape factor, of particle, 213
- E**
 Eaton, J.K., 204, 205
 Edwards, D. A., 193
 Electroactive aniline polymer plates, 151
 Electron
 photoejection process, 47
 trajectories of, 52
 Electron microprobe, 44
 Electron transmission function, 72
 Electrostatic hemispherical analyzer
 components of, 54
 electron, trajectories of
 pass energy, 55
 tangential, 54
 Electrostatic lens, electrons
 acceleration/retardation by, 55
 collection by, 54
 Elghobashi, S.E., 202, 204, 205
 Ellipsoidal particles, drag force for, 210–213
 Ellison, J., 205
 Emend[®], 176
 Emmett, S., 284, 286, 290
 Entocort[®] EC drug, 185
 Enzyme adsorption, 132
 Extents of absorption, 180, 183
 Extracellular polymer substances (EPS), 131
- F**
 Fåhræus–Lindqvist effect, 262
 Fan, F.G., 202–204
 Faxen, H., 201, 208
 FEM. *See* Finite element method
 Fenofibrate drug, 182
 Fernandez de la Mora, J., 202
 Ferrite-nanoparticle–monoclonal-antibody
 conjugates, 11, 12
 Fibrinogen adsorption, 137
 Fichman, M., 202
 Fine-particle active agents, in pharmaceutical
 products methods of preparing, 175–177
 oral delivery of
 food effects on, 180–183
 oral bioavailability, 177–180
 rapid absorption, 183–185
 topical administration to gastrointestinal
 tract, 185, 186
 parenteral administration of, 186–191
 particle transport and deposition process
 adhesion of, 229–238
 aerosol particle motion, 213, 214
 aerosols, 206, 207
 atherosclerosis, 264–267
 blood composition, 259, 260
 Brownian motion process, 221–223
 computer simulation for, 224, 225
 DNS of blood flow, 267–270
 droplets, 209
 ellipsoidal and nonspherical particles,
 210–213
 Fokker–Planck equation, 223
 hydrodynamic forces, 207–209
 lift force of, 217–219
 in lung airways, 239, 240
 in multibifurcation airways, 240–245
 in nasal passages, 239, 240, 245–253
 oral airways, 253–258
 particle motion, equation of, 221
 particle shape factor, 213
 particles on plane, lift force, 219, 220
 red cells, flow behavior, 261–264
 rheology of blood flow, 260, 261
 terminal velocity of, 214–217
 in viscous sublayer, 225–229
 works on, 201–206
 pulmonary delivery of, 191–197
 Finite element method, 267
 First-principles approach, 74
 Fisher, D.M., 239
 Flood gun energy, 59
 Flovent[®] Rotadisk[®], 193
 Flow-Cal 575 fluorospheres
 for CD38 assay, 19
 flow cytometric histogram of, 18
 Flow chamber
 particle/cell suspension, 2
 sheath fluid, 1
 Flow cytometry
 bead chemical sensors for
 application for, 19
 Flow-Cal 575 fluorospheres, 18
 blood analysis by
 CD3 antibody–beads, 4–9
 PS latex beads, 3–4
 CD3/CD3-PE competitive binding
 experiments, 7
 flow chamber, 1
 particle-based immunoassays for, 21

- particle/cell suspension, flow of, 2
- photomultiplier tubes (PMTs), 2
- suspension arrays, 21, 22
- Flunisolide, 191
- Fluorescence-labeled antibody, 25
- Fluorescence resonance energy transfer
 - CdS nanoparticle and PE acceptors, 30
 - nanoparticle donors and tetramethylrhodamine (TMR) acceptors, 32
 - tryptophan residue donors and nanoparticle acceptors, 30, 31
- Fluorescent beads, 17, 18
- Fluorescent dyes, 2
- Fluticasone, 191
- Fokker–Planck equation, 223, 224
- Freeze-dried copolymers, 137
- FRET. *See* Fluorescence resonance energy transfer
- Friedlander, S.K., 202
- Fuchs, N.A., 201
- Full width at half the maximum intensity (FWHM)
 - components of, 105
 - peak decomposition, 78, 79
- Fulwyler, Mack J., 3, 18, 19
- Fung, Y.C., 258, 261

G

- Gallily, I., 204
- 3G8 antibody (IgG1 isotype), 23
- fluorescence intensity, 25
- Gao, X., 297
- Gastrointestinal (GI) tract treatment, topical drug administration, 185–186
- 3G8/3G8-FITC competitive binding trial
 - antibody capture, 27
 - competitive binding, 26
 - fluorescence intensity, 24, 25
 - Langmuir adsorption isotherm, 25
- Giesche, H., 284
- G-jitter excitation, 204, 205
- Goldenberg, M., 204
- Gold nanoparticles
 - on aminodextran-coated PS beads, 34
 - light scattering, 15
 - plasmon extinction bandwidths, 17
- Goldschmidt, V.W., 201
- Goldsmith, H.L., 262
- Gradon, L., 204
- Gram-negative bacteria, 157
- Granulocytes, depletion of, 11

H

- Haefeli-Bleuer (initial not found), 256
- Hahn, I., 246
- Hall, D., 220
- Hamaker constants, for dissimilar materials, 232
- Hamaker, H.C., 232
- Hanratty, T.J., 202
- Harrison, D.G., 265
- Hydrophobicity recovery, 63, 100
- He, C., 202–204
- Hedley, A.B., 202
- Hematite surfaces, 132
- Henglein, A., 28
- Hetsroni (initial not found), 261
- Heyder, J., 239
- HFAs. *See* Hydrofluoroalkanes
- Hidy, G. M., 202
- High-energy milling process, for pharmaceutical manufacturing, 176
- High performance liquid chromatography (HPLC), 290, 291
- Hinds, W.C., 201, 245
- Hinze, J. O., 201, 202
- Histograms, 2
- Hofmann, W., 239
- Holm, R., 109
- Homogenization process, for pharmaceutical manufacturing, 176
- Hook effect, 19, 20
- HP- β -XD. *See* Hydroxypropyl- β -cyclodextrin
- HSA. *See* Electrostatic hemispherical analyzer
- Human oral airways, particle transport and deposition in, 253–258
- Human serum albumin (HSA)
 - adsorbed on polystyrene (PS), 80, 85
 - wide scan XPS spectra of, 49
- Hydrofluoroalkanes, 192
- Hydrogen sulfide gas, microbial production of, 130
- Hydrophobic polymers, surface contamination of, 75
- Hydroxypropyl- β -cyclodextrin, 180

I

- IDD[®]tP MicroParticle technology, 183
- IERF. *See* Intensity/energy response function
- Iglesias, A.J., 239
- Imaging applications, diagnostic, 189, 190
- Inelastic mean free path (IMFP)
 - energy band gap for, 98
 - vs. photoelectron kinetic energy, 71, 72
- Inipenem administration, 188

- Intensity/energy response function
of spectrometer, 72
and XPS data, 73
- Intramuscular drug administration, 188, 189
- Intravenous drug administration, 186–188
- Ion gun, 53
- Itraconazole drug, 188
- J**
- JKR Model, for particle adhesion, 234, 236, 237
- Johnson, J.R., 239
- Johnson, K.L., 234
- Johnstone, H.F., 202
- Joseph, R., 263
- Jou, L.-D., 258, 261, 262
- Jurewicz, J.T., 204
- K**
- Kaazempur-Mofrad, M.R., 262, 267
- Kader, B.A., 202
- Kaiser, C., 284
- Kamm, R.D., 258
- Kelly, J.T., 246
- Kendall, K., 234
- Kerker, M., 32
- Keyhani, K., 246
- Key–lock recognition groups, 298
- Kim, C.S., 239
- Kinkel, J.N., 285, 291
- Kirkland, J.J., 291
- Kleinstreuer, C., 253
- Kricka, L. J., 3
- Ku, D.N., 258
- Kvasnak, W., 202, 204
- L**
- Lactobacillus helveticus* strain, surface
analysis of, 115
- Lactococcus lactis*
surface of, 115
XPS analysis of, 116
- Lane, D.D., 202
- langevin equation, 222–224
- Lattice Boltzmann method, 267
- LBM. *See* Lattice Boltzmann method
- Leal, L.G., 261
- Lee, S.L., 202
- Leighton, D.T., 219
- Lens care solutions (LCS), 158
- Leuprolide acetate, administration, 188
- Levich, V., 201
- Li, A., 202, 204, 224, 239, 241
- Light scatter bead
CD3 antibody–beads, 4–9
PS latex beads, 3, 4
surface plasmon resonance
gold colloid-labeled cells, 15
side scatter intensities, 16
- Light scatter shifts
of antibody-conjugated beads, 16
of metal nanoparticles, 17
- Limit of detection, 109
- Limit of quantification, 109
- Liu, B.Y.H., 202
- Liversidge, G.G., 179, 180
- Loratadine, 177
- Low Reynolds number (LRN) k - ω turbulence
model, 253
- Lumley, J.L., 201
- Lysozyme molecules, 147
- M**
- Magnetic beads
CD45 antibody-conjugated, 9
depletion characteristics of
CD8+ lymphocytes, 14
granulocytes, 11
leukocytes, 14
neutrophils, 11, 12, 26
RBCs, and platelets, 11, 12
WBCs, 9
normal cells, removal of, 14, 15
size distribution and magnetism in, 9
- Ma, J., 295
- Mammalian cell surfaces, analysis of, 152, 153
- Manganese ferrite nanoparticles
monoclonal antibodies conjugated, 11
SEM photomicrograph of, 10
size distribution of, 9, 10
- Maranzano, B.J., 290
- Markowitz (initial not found), 285
- Marshall, C., 110
- Marshall, J.R., 205
- Martonen, T.B., 239, 246
- Mass median aerodynamic diameter, 192
- Matrix metalloproteinases, 265
- Maugis, D., 235
- Maugis–Pollock model, 235, 236
- Maxey, M.R., 201
- Ma, Y., 295
- Mazaheri, A.R., 239, 241, 243, 245
- McCoy, D. D., 202
- Mckee, S., 202
- McLaughlin, J.B., 203, 204, 218
- MCPI. *See* Monocyte chemoattractant
peptide-1

- Megace[®]gES. *See* Megestrol acetate drug
Megestrol acetate drug, 181
Mei, R., 218
Meloxicam, 183, 184
Mercer, T.T., 201
Merret, K., 138
Metal ion species, 130
Metal nanostructures, scattering excitation profiles for, 16, 17
Methyprednisolone acetate administration, 188
Microbial sample preparation, XPS approaches, 116
freeze drying, 117
Saccharomyces cerevisiae
freeze dried, 117, 118
with nonmonochromatized radiation, 119
vitrification, 118
Microbial surfaces, 129
liquid environment, interactions between, 130
molecular composition of, 114, 115
Microbiologically influenced corrosion (MIC), 133
Microemulsion technique, 285
Microfluidizer[®], 176
Microorganisms
bioleaching, 132
material surface conditioning with, 131
surface analysis of, 109, 134
Azospirillum brasilense, 122
Bacillus subtilis, 110, 111
Lactobacillus helveticus strain, 115
Ph. cryosporium, 115
Pseudomonas fluorescens strain, 114
surface composition of
Azospirillum brasilense, 122, 123
brewing yeasts, 121, 122
gram-positive and gram-negative bacteria, 120, 121
hydrophobicity, relations with, 126, 127
surface electrical properties, relations with, 124–126
Middleman, S., 201
Millard, M.M., 110, 153
Milne, S.J., 286
Mineral surface, 132
MMAD. *See* Mass median aerodynamic diameter
MMPs. *See* Matrix metalloproteinases
Mobic[®]. *See* Meloxicam
Mollinger, A.M., 220
Molybdate, 130
Monoclonal antibody-conjugated magnetic beads, 13, 14
Monoclonal-antibody conjugates
CD101 and CD160, 22, 23
ferrite-nanoparticle, 11
Monocyte chemoattractant peptide-1, 265
Mononuclear phagocytic system, 187
Monte Carlo simulation technique, 256
MPS. *See* Mononuclear phagocytic system
Muller, V.M., 235
Multi-analyte detection system, 19
Myoglobin, 147
- N**
NanoCrystal[®] colloidal dispersion, of meloxicam, 184
NanoCrystal[®] technology, 176
NanoCrystal solid dosage, 184
Nanoparticle bead
fluorescence emission
PS fluorospheres, 18
silica-fluorescent dye beads, 20, 21
magnetic beads, 9–14
surface plasmon resonance
gold/silver nanoparticles, 16, 17
metallic microrods, 15
Naprosyn[®], 188
Naproxen drug, 188
Nasal passages, particle transport and deposition in, 245–253
Natan, M., 15
Nerem, R.M., 265
Neutrophils
1D3 antibody–ferrite bead titers effects on, 12–13
depletion efficiency graph for, 11, 12
Newton regime, 207
Nieuwstadt, F.T.M., 220
Nitrogen signal, 138
Nonspherical particles, drag force for, 210
Nonsteroidal anti-inflammatory drugs (NSAIDs), 183
Noyes–Whitney equation, 179
- O**
Octreotide acetate, administration, 188
Omron MicroAir[®], 195
Oral bioavailability, of drugs, 177–180
Organic emitters, 17
Ostrander, K. D., 195
Ounis, H., 202–204, 223, 225, 226
Ozin, A., 287
- P**
Paiva (initial not found), 256
Papavergos, P.G., 202
Particle-based immunoassays, 21, 22

- Particle/cell suspension, 2
 Particle deposition rate, simulation of, 202–204
 Particle image velocimetry, 246
 Particulate matter (PM) deposition, 239, 240
 Patterson, G.S., Jr., 202
 Paynter, R.W., 151
 Peak decomposition
 potentialities and limitations of, 85, 86
 procedure description, 78, 79
 Peak smoothing, 77
 Peak width, 105
 Peclet number and nose capture efficiency,
 251, 252
 Pentaamineruthenium, 147
 Peroxisome proliferator-activated receptor α ,
 182
 PET, modification scheme of, 140
 Pharmaceutical dosage forms, composition of,
 175
 PHEMA grafts
 C 1s peak of, 101
 surface reorganization of, 100
 Phenacetin drug, 179
 Phosphate buffer saline (PBS), 131
 Photoelectric effect, 46
 Photoelectrons
 inelastic collisions, 48, 50
 injection of, sample, 55
 Photolithography, 142, 143
 Photomultiplier tubes, 2
 3-D Photonic-bandgap structures, 287, 288
 Phycoerythrin (PE), bilin groups in, 21
 Physical adsorption, 139, 145, 149
 PIV. *See* Particle image velocimetry
 Plasma discharge, 142
 Plasma polymerization, 138, 142
 Plasma-sprayed surfaces, 135
 Plasmon structures, 67
 Platelet-rich plasma, 137
 Platelets (PLTs) consumption
 by polyurethanes, 136
 depletion efficiency graph for, 11, 12
 Pluronic adsorption, 149
 pMDI. *See* Pressurized metered-dose inhaler
 PMTs. *See* Photomultiplier tubes
 Pollock, H.M., 235
 Polychromatic X-ray beam, 53
 Polyclonal antibody, 130
 Poly(ethylene oxide) (PEO), 137
 Polystyrene latex beads
 for blood cell analysis
 diameter of, 5
 light scatter patterns of, 3
 for CD16 antigen, 22
 Polyurethane vascular grafts, 152
 Polyvinylpyrrolidone, 180
 Pore structure
 controlled, 297
 octahedral/tetrahedral, 286
 Porous solids, 43, 44
 Powder sintering, 286, 287
 Pozrikidis, C., 258, 267
 PPAR α . *See* Peroxisome proliferator-activated
 receptor α
 Prednisone drug, 191
 Prescott, L. F., 179
 Pressurized metered-dose inhaler, 191
 in fine particle delivery, 194, 195
 Proctor, D.F., 245
 Prolate ellipsoid of revolution, motion of, 211
 Protein adsorption, 131, 132
 Pruitt, J. D., 179, 183
Pseudomonas fluorescens strain, 114
 PS latex beads. *See* Polystyrene latex beads
 PS–magnetite beads
 light scatter shifts in, 9
 Pulmicort[®] Respules[®], 195
 Pulmicort[®] Turbuhaler, 192
 Pumping systems
 as contamination source, 75
 used on XPS spectrometers, 52
 PVP. *See* Polyvinylpyrrolidone
- Q**
 QbeadTM, 29
 Qi, D., 270
 Quantum dotencoded bead system, applica-
 tions of, 29
- R**
 Raabe, O.G., 240
 RAFC/RACS. *See* Raman-activated flow
 cytometer/cell sorter
 Raman-activated flow cytometer/cell sorter, 32
 Rapamune[®], 176
 Reactive oxide species, 265
 Red blood cells (RBCs), depletion effi-
 ciency graph for, 11, 12
 Reeks, M.W., 202
 Respirable inhalation powders, preparation of,
 193
 Respiratory aerosols, in respiratory disease
 treatment, 191, 192
 Reynolds number, 207
 Rhone-Poulenc magnetic latex beads, 9, 10
 Riley, J.J., 202
 Risperidone, administration, 188
 Rizk, M.A., 202
 Roberts, A.D., 234

- ROS. *See* Reactive oxide species
Rouhiainen, P.O., 202
Ruddy, S. B., 185, 186
Ryde, N. P., 179
- S**
- Saccharomyces cerevisiae*, 130
 precision of analysis of, 119, 120
 sample preparation
 freeze dried, 117, 118
 with nonmonochromatized radiation, 119
 scanning electron micrographs of, 117
 XPS analysis of, 118
Saffman, P.G., 217, 218, 221
Sample preparation
 adsorbed biomolecules, 99, 100
 low temperature analysis, 101, 102
 sample alteration during, 102, 103
 surface reorganization, 100, 101
Schamberger, M. R., 204
Scherer, P.W., 247
Schiller, C.F., 239
Schreck, S., 246
Schroter, R.C., 239
Secondary electrons, 56
Sehmel, G.A., 202
Seinfeld, J.H., 201
Semiconductor nanoparticles
 close packing of, 29
 luminescence emission, 27, 28
Sensitivity factors, spectrometer, 74
SERS. *See* Surface enhanced Raman scattering
Shams, M., 225
Shan (initial not found), 269
Shapiro, M., 204
Signal/noise ratio (S/N), XPS instruments, 105–107
Siiman, O., 1–36
Silica-fluorescent dye beads, concentration quenching of, 20, 21
Silicate glass surfaces, 132
Silicon wafers
 for atomic force microscope investigations
 XPS spectra of, 90
 Auger peaks, background rise, 62
 wide scan spectra of, 61
Silver nanoparticles
 on aminodextran-coated PS beads, 34
 elastic light scattering work on, 34
 light scattering, 15
 plasmon extinction bandwidths, 17
Skalak, R., 258, 261
Smith, D.H., 204
Snyder, W.H., 201
So, J-H, 290
Soltani, M., 203, 204
Spurny, K.R., 201
Squire, J.M., 266
Squires, K.D., 204
SRB. *See* Sulfate-reducing bacteria
Stachiewiz, J.W., 202
Steric repulsion, 130
Stöber silica particles
 medical applications of, 297–299
 preparation of, 283–285
 surface and bulk modifications of, 285
 technological applications of
 chromatography, 290–295
 3-D photonic-bandgap structures, 287, 288
 hard sphere suspensions, rheology of, 290
 particle packing and pore structure, 286
 pigments, 295–297
 powder sintering, 286, 287
 sensors, 289
Stock, D.E., 202, 204
Stokes drag force, 207
Stopping distance, of particle, 215
Streptococcus sobrinus, 130
Strong J. C., 246
Stukel, J.J., 202
Sulfate-reducing bacteria, 130
Supercritical fluids, usage of, 177
Surface analysis
 vs. bulk analysis
 depth profiling, 129
 force–distance curves, 128
 infrared bands, 127
 methods of, 48–51
 of microorganisms, 109
 Azospirillum brasilense, 122
 Bacillus subtilis, 110, 111
 Lactobacillus helveticus strain, 115
 Pseudomonas fluorescens strain, 114
 quantitative relationships
 peak shape and elemental composition, 114
 polysaccharides, 113, 114
 proteins and esterphosphates, 113
 proteins and polysaccharides, 112, 113
Surface chemical composition, 138
Surface coverage, 145
Surface electrical properties, 129
Surface enhanced Raman scattering, 32
 of gold nanoparticles, 32, 33
 red-shifted wavelength, 36
 of R6G
 on gold nanoparticle/PS beads, 35
 on silver nanoparticle/PS beads, 36

- Surface modifications, 139
 biological exposure, 149
 bacterial culture, 150
 explantation, 151
 of biomaterials, 142
 by immobilization, 141
 Surface-modified materials, 138
 Surface reorganization
 freeze-drying, 118, 123
 silicone rubber substrate, 100
 Surface topography, 135
 Suspended particle dispersion, computer
 simulation techniques for, 202–204
 Swift, D.L., 239, 245, 246, 250
- T**
 Tavoularis, S., 202
 Taxotere[®], 187
 Tchen, C.M., 201
 Tetraethoxysilane (TEOS), 283
 Therapeutic active agent, topical administration
 of, 185, 186
 Tian, L., 239, 240
 Tissue-culture polystyrene (TCPS), 142
 Toporov, Y.P.T., 235
 Triamcinolone acetonide, 191
 TriCor[®], 176, 182
 Triglide[™]. *See* Fenofibrate drug
 Trinh, E.H., 205
 Trusdell, G.C., 202
 Triptorelin pamoate, administration, 188
 Tunable synchrotron sources, 53
 Twomey, S., 201
- U**
 UHV. *See* Ultra-high vacuum
 Ultra-high vacuum
 contamination sources in, 74, 75
 Photoelectron spectroscopy, 46
 Ultraviolet Photoelectron Spectroscopy (UPS),
 46
 Unger, K.K., 290, 291
 Uronic acids, 131
- V**
 Vacassy, R., 295
 Vacuum-dried copolymers, 137
 Van der Waals force, for particle, 230–232
 Van Helden, A.K., 284, 290
 Vascular cell adhesion molecule-1, 265
 VCAM-1. *See* Vascular cell adhesion
 molecule-1
 Vibrational fine structure, 67
 Vinals, J., 205
- Vincent, J.H., 201
 Vink, H., 266
 Vrij, A., 284
- W**
 Wagner, J., 290
 Wagner, M. S., 148
 Wang, L.-P., 202
 Wang, Q., 204
 Wang, Z., 206
 WBCs
 biological assays for, designing, 3
 depletion of, leuko-rich sample, 9–11
 enumeration of subsets of, 11, 12
 light scatter markers for, 11
 Weibel, E.R., 240, 256
 Weinbaum (initial not found), 266
 Wood, N.B., 202
 Wood, P.E., 204
 Wright, J., 4
- X**
 xMultianalyte Profile (xMAP[™]) technology,
 21
 XPS applications
 interfacial phenomena, microorganisms, 129
 biomedical applications, 133
 marine bacterial strains analysis, 130
 surface composition, 129
 XPS imaging, image acquisition
 parallel, 57
 serial, 56
 XPS peaks
 binding energy of, 48
 homogeneous solid, 49, 50
 human dental enamel, 57, 59
 XPS spectra
 analyzed zone as homogeneous
 adsorbed contaminants, influence of, 74,
 75
 dipalmitoyl phosphatidylcholine (DPPC),
 76
 first-principles approach, 74
 general expression for, 73, 74
 sensitivity factors, 74
 Auger peaks
 and Auger parameter, 64, 65
 photoionization and, 63, 64
 energy scale referencing
 binding energy, 61
 kinetic energy, 60
 photoelectron peaks and background
 background intensity, 62
 energy loss, 61

- photoionization cross-section, 70
 - quantification of
 - basic equation for, 69, 70
 - sample irradiation, X-rays and emitting photoelectrons, 67–69
 - secondary lines due to
 - multiplet splitting, 66
 - plasmon structures, 67
 - shake-up satellites, 66, 67
 - source satellites, 65, 66
 - valence band
 - factors affecting spectrum in, 63
 - spectra of LLDPE and PP, 62, 63
 - XPS spectrometer
 - analyzed zone, heterogeneity of
 - aluminum coating, 89
 - background shape, 89
 - function of tilting, 87
 - chemical shifts
 - biochemical compounds, 80–87
 - polymers, 79, 80
 - components of, 51
 - data interpretation, by simulation
 - continuous adlayer, 90–94
 - discontinuous adlayer, 94–97
 - mixture of particles, 97
 - rough surfaces and porous solids, 97
 - data interpretation, general
 - background subtraction, 77, 78
 - peak decomposition, 78, 79
 - peak smoothing, 77
 - instrument setting
 - accuracy, 107–109
 - artifacts, 104, 105
 - limit of detection and quantification, 109
 - peak width, 105
 - signal/noise ratio, 105–107
 - intensity/energy response function (IERF)
 - of area of collection, 72
 - dependence on, 73
 - lens system and energy analyzer, 54, 55
 - performance evaluation criteria for, 103
 - pumping systems, 52
 - sample handling
 - powder specimens, 52
 - specific accessories, 53
 - sample preparation
 - adsorbed biomolecules, 99, 100
 - low temperature analysis, 101, 102
 - sample alteration during, 102, 103
 - surface reorganization, 100, 101
 - schematic representation of, 47
 - systematic errors, 108
 - vacuum in, importance of, 52
 - X-ray sources
 - metal target, 52
 - tunable synchrotron sources, 52, 53
 - X-ray fluorescence, 104
 - X-ray image enhancement, application of, 189, 190
 - X-ray photoelectron spectroscopy
 - analyzed area, 56
 - applications, 44 (*see also* XPS applications)
 - chemical composition analysis, 44
 - constant analyzer energy (CAE) mode, 55
 - dental implants, 135
 - electron energy levels, 48
 - electron multipliers, 56
 - image acquisition
 - parallel, 57
 - serial, 56
 - limitations of, 149
 - line scans of, 143
 - microbial sample preparation
 - approaches, 116
 - freeze drying, 117
 - saccharomyces cerevisiae*, 117, 118
 - vitrification, 118
 - principle of
 - electron photoejection process, 47
 - kinetic energy, electrons, 46
 - photoelectric effect, 46
 - surface composition, 138
 - thin layer analysis, 50
 - X-ray sources
 - magnesium, 65
 - metal target, 53, 54
 - monochromatized, 105
 - Xu, H., 298
- Y**
- Yaglom, A.M., 202
 - Yates, B., 202
 - Yin, Y., 286
 - Yoshinaga, K., 285, 291
 - Yu, C.P., 204
 - Yu, G., 247
- Z**
- Zahmatkesh, I., 253, 254
 - Zamankhan, P., 247, 248, 250
 - Zhang, H., 203, 204, 239, 245
 - Zukoski, C.F., 284